🔗 Share this article

While America undertakes historic adjustments to its immunization guidelines, a particular individual appears unexpectedly: Høeg, a Danish American sports physician and epidemiologist who rose to prominence by casting doubt on Covid vaccines in the pandemic and has concentrated on potential fatalities after Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Public health authorities planned to announce radical changes to the childhood vaccination calendar in December, synchronizing the US with the Danish national calendar, according to reports – a major change that would place the US out of alignment with a large portion of the world with little proof for public health gain. The planned update has been delayed until the next year.

Rather than the top vaccines chief, Dr. Høeg is listed to speak at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

A New Direction at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has frequently advocated for discontinuing some pediatric vaccine recommendations in the US to become more in line with the Danish model, a society with nationalized medicine and a number of inhabitants approximately the size of Wisconsin’s.

So far statements, she has kept her attention on vaccines – typically the responsibility of Prasad, chief of the FDA’s CBER – rather than drug regulation.

Questions Over Background

Dr. Høeg has no apparent background in pharmaceutical research, oversight or management, which has been typical for former leaders of the biologics center. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a clinical trial. She has no expertise in running a large organization. She has no expertise in drug approvals.”

Past heads of CBER would “grasp laws and regulations and the research of medication creation”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that previous people who headed the center have had.”

CDER has an vast workload at the FDA, she pointed out.

“The public just pays attention on the innovative therapies, but the generic program clears thousands of generic drugs. There is also a biosimilars program, over-the-counter program and more, and each of these need to be supervised,” she explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the job, which oversees over 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” the former official concluded.

Response and Controversial Policies

Regarding inquiries about Dr. Høeg's credentials and whether this assignment represents greater collaboration among agency officials on vaccines, a spokesperson stated that the “inquiries are based on incorrect presumptions”.

“This background aligns with the functions of her role,” the representative explained, pointing to the months Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s new priority voucher program, a controversial one-day therapy clearance system that reportedly worried her preceding directors. “How are these drugs being picked for this fast-track system? Who makes the choices?” Dr. Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards more relaxed regulations of pharmaceuticals, aside from shots.”

Established History on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if troubling, track record, critics observe. She released a analysis using unconfirmed volunteer-provided data to assess the frequency of myocarditis after COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new administration included altering regulations for recently developed shots and halting “unnecessary” vaccines, she said after the election on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of barring young men from obtaining Covid vaccines.

“She’s an all-around true believer who starts off with her preconceived notions and reverse-engineers to retrofit the science in a extremely disingenuous, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined other dissenters, {like|